Roche (OTCMKTS:RHHVF)‘s stock had its “buy” rating restated by stock analysts at The Goldman Sachs Group in a research report issued to clients and investors on Friday, AnalystRatings.com reports.
A number of other brokerages have also recently weighed in on RHHVF. UBS Group restated a “hold” rating on shares of Roche in a research report on Tuesday, March 23rd. JPMorgan Chase & Co. restated a “hold” rating on shares of Roche in a research report on Monday, April 19th. Barclays restated a “buy” rating on shares of Roche in a research report on Wednesday, April 21st. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Roche in a research note on Wednesday, April 21st. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold”.
Shares of RHHVF stock opened at $375.20 on Friday. Roche has a fifty-two week low of $308.57 and a fifty-two week high of $388.50. The firm has a fifty day moving average price of $338.35.
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation.
Featured Article: Blue-Chip Stocks
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.